SAVI applicator removes obstacles associated with brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

TORONTO-Studies out of the University of California, San Diego, have demonstrated that the SAVI radiation device offers coverage of the breast cancer tumor bed while sparing normal tissue from radiation.

TORONTO-Studies out of the University of California, San Diego, have demonstrated that the SAVI radiation device offers coverage of the breast cancer tumor bed while sparing normal tissue from radiation.

There were no infections, persistent seromas, or local recurrences of cancer among any of the patients in two separate investigations conducted by Daniel Scanderbeg, PhD, and Catheryn Yashar, MD, both from the university's Moores Cancer Center. They presented their findings at the 2009 American Brachytherapy Society meeting. Dr. Scanderbeg's group retrospectively evaluated 13 breast cancer patients with breast cancer tumor cavities less than 7 mm from the skin surface.

Dr. Yashar's team reviewed early clinical experiences with SAVI in 40 breast cancer patients, nearly half of whom were not candidates for balloon brachytherapy due to skin spacing or small tumor size. They concluded that the device allowed for planning flexibility, easier insertion, and minimal exposure.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content